These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 9691110)
1. Treatment of Crohn's disease at the turn of the century. Bickston SJ; Cominelli F N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110 [No Abstract] [Full Text] [Related]
2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103 [TBL] [Abstract][Full Text] [Related]
3. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Feagan BG; Sandborn WJ Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239 [TBL] [Abstract][Full Text] [Related]
4. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504 [TBL] [Abstract][Full Text] [Related]
5. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Bauditz J; Lochs H; Schreiber S N Engl J Med; 1998 Jan; 338(5):334. PubMed ID: 9446035 [No Abstract] [Full Text] [Related]
6. [Drug therapy of Crohn disease]. Niemelä S Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446 [No Abstract] [Full Text] [Related]
7. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease. Rutgeerts P Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451 [No Abstract] [Full Text] [Related]
9. Algorithm for the treatment of Crohn's disease: incorporation of emerging therapies. Souney PF Am J Gastroenterol; 2000 Sep; 95(9):2381-3. PubMed ID: 11007248 [No Abstract] [Full Text] [Related]
10. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E; Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560 [TBL] [Abstract][Full Text] [Related]
15. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation]. MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443 [No Abstract] [Full Text] [Related]
16. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. Rutgeerts P Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597 [TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?]. Bischoff A MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159 [No Abstract] [Full Text] [Related]
18. [Maintaining a remission]. Fleig WE; Z Gastroenterol; 2003 Jan; 41(1):36-42. PubMed ID: 12541172 [No Abstract] [Full Text] [Related]
19. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Sandborn WJ; Feagan BG Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211 [TBL] [Abstract][Full Text] [Related]
20. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease. Feagan BG Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385 [No Abstract] [Full Text] [Related] [Next] [New Search]